We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Douglas
Easton
dfe20@medschl.cam.ac.uk
Ms
Joanna
Mitchell
EMBED@medschl.cam.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasm of breast
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Women at high risk of developing breast cancer often undergo a double mastectomy. Detecting the disease at an earlier stage could be a major step forward to eliminate the need to have risky surgery.
There has been considerable interest recently in using blood-markers in the early detection of cancer. ctDNA (circulating tumour DNA) is released by cancer cells into the blood-stream and is now an important blood-marker in advanced disease. The aims of this study are two-fold: (i) to further develop and use sensitive state-of-the-art assays to detect small amounts of ctDNA in the blood with increased sensitivity and (ii) to measure ctDNA over time in women who develop breast cancer. Using these blood-markers it may be possible to detect breast cancer at a much earlier stage.
We aim to recruit two cohorts of women:
(i) Cohort 1: Approximately 2700 women with a strong family history of breast cancer. These women will be asked to provide annual blood samples and complete some questionnaires for up to 3 years initially or until they receive a clinical diagnosis of breast cancer. For women who develop cancer we will analyse the ctDNA in the blood samples collected at the time closest to diagnosis. We will also obtain mammogram images and tumour samples to guide a more sensitive analysis. Following this, we will analyse the blood samples collected at other time points to establish the earliest point at which ctDNA can be detected in the blood.
(ii) Cohort 2: We aim to recruit at least 100 women who have been recalled to the Breast Unit because of abnormalities seen on their recent mammogram (in Cambridge only). We will take blood samples from these women to refine and validate the ctDNA assays in readiness for use with cohort 1.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Women who are known carriers of the common pathogenic gene mutations (e.g. BRCA1 and BRCA2).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Douglas
Easton
dfe20@medschl.cam.ac.uk
Ms
Joanna
Mitchell
EMBED@medschl.cam.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 45002
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
